Eurofins buys Element's North American testing arm for $400M

What's the deal? Eurofins ScientificDealroom has a profile for this one. Try Dealroom → has agreed to acquire Element Materials Technology's North American Life Sciences Testing Services business for $400 million. The deal deepens the multinational testing firm's presence across the United States and Canada.

What's the endgame? The acquisition adds a network of laboratories, staff, and digital laboratory platforms to Eurofins' portfolio. It is expected to close in the fourth quarter of 2026.

Why now? The US market for contract life-sciences testing is estimated at $15 billion a year, growing at 6.5% annually over the next decade. Eurofins currently holds about 12% of that market, with a net profit margin of 12.8%.

What could go wrong? Eurofins faces well-resourced incumbents including Thermo Fisher Scientific, QIAGENDealroom has a profile for this one. Try Dealroom →, and Agilent Technologies, all of which are heavily invested in digital automation and cloud-based analytics. Acquiring Element's digital platform is meant to position Eurofins as a technology-enabled alternative in a higher-margin niche.

By the numbers: Alongside the deal, Eurofins completed a week-long share buyback of roughly 100,000 shares at an average price of €69.35, totalling about €6.9 million over five trading days. With a debt-to-equity ratio near 0.35 and a free-cash-flow yield of 4.2%, the buyback signals confidence in its valuation while lifting earnings per share.

The signal: Eurofins is balancing shareholder returns with portfolio expansion as regulatory demands tighten and rivals race to automate. The move reflects a broader consolidation trend among life-sciences service providers competing for recurring contract-testing revenue.

Read more: Aktiensensor